The Pharmaletter

Candel Therapeutics

A clinical-stage oncology company developing off-the-shelf viral immunotherapies designed to generate an individualized anti-tumor immune response inside a patient’s tumor.

Company Overview

Candel develops viral immunotherapies intended to turn tumors into in situ vaccines. Its lead candidate, CAN-2409, is designed for intratumoral injection and paired with an oral prodrug to trigger tumor cell death and immune activation.

The company’s near-term priority is advancing CAN-2409 in localized, intermediate-to-high-risk prostate cancer. Additional development has explored lung and pancreatic cancers.

A second platform, CAN-3110, targets recurrent high-grade glioma using an engineered herpes simplex virus designed for immune activation in the brain.

Headquarters and Global Presence

Candel is headquartered in Needham, Massachusetts.

Clinical trials are conducted through specialist oncology and neuro-oncology centers, with an operating structure typical of a lean development-stage biotech.

Founding and History

Candel was formed around two engineered viral immunotherapy platforms with the aim of creating scalable, off-the-shelf cancer treatments.

In recent years, the company has concentrated resources on prostate cancer while continuing early-stage work in glioma and selected solid tumors.

Therapy Areas and Focus

Candel’s priority indications include:

Localized prostate cancer
Non-small cell lung cancer
Pancreatic ductal adenocarcinoma
Recurrent high-grade glioma

The strategic emphasis is on tumors where local immune priming may enhance standard treatments.

Technology Platforms and Modalities

Adenovirus platform (CAN-2409)
CAN-2409 is a replication-defective adenoviral vector delivered directly into tumors. It is paired with an oral prodrug to generate targeted tumor cell death and immune activation.

The program is positioned for use alongside standard therapies, such as radiation in prostate cancer.

HSV platform (CAN-3110)
CAN-3110 is an engineered herpes simplex virus designed for repeat dosing in brain tumors. It aims to stimulate immune responses within the tumor microenvironment of recurrent glioma.

Key Personnel

Paul Peter Tak, President and Chief Executive Officer
Laura K. Aguilar, Chief Medical Officer
Nathan Caffo, Chief Business Officer

Strategic Partnerships

Candel’s strategy is primarily internally driven, with partnering most relevant at later stages for scale-up and commercialization.

Manufacturing and clinical collaboration are key enablers given the complexity of viral therapy production and multicenter oncology trials.

FAQ Section

Candel develops viral immunotherapies designed to stimulate anti-tumor immunity directly within the tumor microenvironment. Its platforms use engineered adenovirus and herpes simplex virus vectors to deliver gene payloads that promote tumor cell killing and immune activation.

Candel focuses on solid tumors, with priority in localized prostate cancer and recurrent high-grade glioma. Additional exploration has included lung and pancreatic cancers where immune activation strategies may complement standard care.

Key disclosed programs include:

CAN-2409: late-stage development in localized prostate cancer; earlier-stage evaluation in lung and pancreatic cancers

CAN-3110: Phase I development in recurrent high-grade glioma

The company has emphasized clinical results in prostate cancer demonstrating immune activation and clinical benefit when combined with standard-of-care radiation.

The registrational strategy centers on confirming durable outcomes and demonstrating additive benefit versus standard therapy alone.

Near-term milestones include regulatory discussions for CAN-2409 in prostate cancer and alignment on submission strategy.

Additional milestones include continued development decisions in lung cancer and progression of CAN-3110 through early-stage glioma studies.

Primary value drivers include:

Execution of a clear regulatory path for CAN-2409
Demonstration of durable clinical benefit in prostate cancer
Early proof-of-concept signals for CAN-3110 in glioma

Key watchpoints include consistency of clinical benefit in larger datasets, reproducibility of manufacturing at scale, feasibility of repeat dosing for viral therapies, and the ability to compete in increasingly complex oncology treatment landscapes involving combination regimens.

Want to Update your Company's Profile?